Navigation Links
DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Date:4/1/2008

EL SEGUNDO, Calif., April 1, 2008 /PRNewswire/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease, today announced its former Chief Medical Officer (CMO) Charles J. McAllister, M.D. will retire effective April 1, 2008. Dr. McAllister stepped down as CMO in July 2007, and has since served as CMO emeritus in the Office of the CMO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

"Charlie has provided 30 years of incredible service to kidney care patients and the broader kidney care community, as a practicing nephrologist, as a hospital chief of staff and as DaVita's chief medical officer," said DaVita CEO Kent Thiry. "The combination of his energy, his intellect, his sense of humor and his warm bedside manner is amazing."

Dr. McAllister served as CMO for DaVita(R) since 2000. During that time, his dedication to continuous improvement in the areas of physician performance management, national clinical measurement development, product evaluation and testing, and clinical compliance program implementation, among others, helped DaVita become a national leader in clinical outcomes. Dr. McAllister's efforts also helped shaped DaVita's community-like work environment, which has been broadly written about and is taught at many major business schools.

"Dr. McAllister really represents the life-force of the Physician Council at DaVita, serving as DaVita's physician beacon of outstanding and compassionate care for our most vulnerable patients," said John Robertson, M.D. "All of the physicians remaining with the Office of the Chief Medical Officer will continue to aspire to the same level of professionalism and integrity that Charlie single handedly inspired since the day he joined with DaVita."

Prior to serving as CMO for DaVita, Dr. McAllister served as vice president of medical affairs for Gambro and Vivra, respectively. He also spent more than 20 years as medical director of dialysis facilities in the Tampa Bay area, where as one of the first practicing local nephrologists, he created dialysis programs serving a community of more than one million people.

"Of my major accomplishments, I'm especially proud of being given the honor to work with many colleagues, nurses, dieticians and others -- I was able to learn from them all," said Dr. McAllister. "As I retire from my executive career, I plan on working in the not-for-profit sector with the disadvantaged and underserved. I'm actually looking forward to putting back on my white coat and stethoscope."

Dr. McAllister has accepted a part-time position as medical director with Bay Area Treatment Center in Pinellas Park, Fla., where he will work with individuals suffering from substance dependence.

The Office of the CMO replaced the position of DaVita CMO on July 1, 2007. Membership comprises John Robertson, M.D., David Van Wyck, M.D. and Robert Provenzano, M.D.; and Allen Nissenson, M.D. serves as Special Advisor to the Office of the CMO.

DaVita is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages over 1,300 outpatient facilities and acute units in over 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients. For more information, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical Announces Needle Supply Agreement with DaVita
2. DaVita to Present at UBS Best of Americas Conference
3. Human Pheromone Sciences Announces Quarterly and Full Year Results
4. Dragon Pharma announces 2007 full year financial results
5. Genaera Corporation Announces 2007 Financial Results
6. Genmab Announces Year End 2007 Financial Results
7. Immunosyn Corporation Announces 2007 Results, Files 10KSB
8. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
9. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
10. China Pharma Holdings, Inc. Announces Record 2007 Year End Results
11. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Wash., Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ... brachytherapy and medical radioisotope applications for the treatment of ... today announced its financial results for the second quarter ... 31, 2015. --> ... quarter of fiscal 2016, which ended December 31, 2015, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated network ... two long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical ... Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will assume ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of ... on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert ...
(Date:2/10/2016)... ... February 10, 2016 , ... Global Stem ... agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate Global ... in the latest adipose and bone marrow therapies. , Through the new ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:1/27/2016)... Jan. 27, 2016  Rite Track, Inc. a leading ... West Chester, Ohio announced today the ... staff, based in Austin, Texas , ... to provide modifications, installations and technical support offerings for ... of PLUS, commented, "PLUS has provided world class service ...
Breaking Biology News(10 mins):